Business
Cannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors
Cannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, June 16, 2020\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, June 16, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Dr. Erez Scapa to its Scientific Board of Advisors. \n\n \n \n \n \n \n \n\n \nDr. Scapa, an Expert in Invasive Gastroenterology in the Sourasky Medical Center in Tel-Aviv, Israel, will join the company's scientific board of advisors, moving forward with the clinical validation of the safety and efficacy of the company's novel cannabis formulations for the treatment of colon cancer.\nDr. Scapa earned his M.D in 2000 at the Technion Institute of Technology in Haifa, Israel, cum laude. He later held a Research Fellowship in Hepatology at the Brigham and Women's Hospital, Harvard University, Boston, MA, as well as a fellowship in Endoscopic Submucosal Dissection at the NTT Medical Center in Tokyo, Japan. He is an expert in invasive Endoscopy and has extensive experience in preforming colonoscopies and gastroscopies. He is proficient in both diagnostic as well as invasive Endoscopic US (EUS) and serves as the head of the Endoscopic Submucosal Dissection (ESD) program in Tel-Aviv Sourasky Medical Center, initiated in 2019. \nBased on previously held pre-clinical trials at the company's High Throughput Screening (HTS) facility in Israel, exhibiting cannabinoids demonstrating positive differential necrotic effects of cannabinoids on colon cancer cells, the company continues to expand its efforts into cancers of the Gastrointestinal tract.\nEyal Barad, Cannabics' Co-Founder and CEO, commented: \"We are grateful to be joined by Dr. Scapa. His knowledge, expertise and deep understanding in Gastroenterology wi...